Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cell Genesys, a biotechnology company, and Takeda Pharmaceutical Company, together with its wholly owned subsidiary Millennium Pharmaceuticals, have mutually agreed to suspend the further development of Gvax immunotherapy for prostate cancer.
Subscribe to our email newsletter
Takeda has also ended the collaboration agreement with Cell Genesys for the development and commercialization of the product.
Under the terms of the agreement, Takeda will return all commercial rights to Gvax immunotherapy for prostate cancer to Cell Genesys and make certain wind-down payments to Cell Genesys in connection with the phasing out of the remaining clinical development activities.